Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
07 déc. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription...
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
14 nov. 2023 14h01 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication...
Repligen Corporation to Present at Upcoming Investor Conferences
07 nov. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
02 nov. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
31 oct. 2023 07h30 HE
|
Repligen Corporation
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to...
Repligen to Report Third Quarter 2023 Financial Results
17 oct. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31,...
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
02 oct. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
26 sept. 2023 07h30 HE
|
Repligen Corporation
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag...
Repligen Appoints Jason K. Garland as Chief Financial Officer
12 sept. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
01 sept. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...